Summary:
A Phase 3, double-blind, randomized, placebo-controlled, multi-center, fixed-dose, parallel group efficacy and safety in pediatrics (6-17) with Attention-Deficit/ Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate)
Qualified Participants Must:
• Be 6 - 17 years old
•
Be diagnosed with ADHD
•
Be in general good health
Qualified Participants May Receive:
Up to $850 for time and travel